T1	Participants 92 170	599 evaluable patients with benign prostatic hypertrophy at 7 urological units
T2	Participants 251 441	group 1--197 patients given single-dose ceftriaxone (2 gm.), group 2--203 patients given 160/800 mg. trimethoprimsulfamethoxazole and group 3--199 controls given no antimicrobial prophylaxis
